TheEdgeResearch
Home / Stocks / LCTX

Lineage Cell Therapeutics, Inc. (LCTX)

AMEX Healthcare Biotechnology
$0.77 ▼ -5.87%
Market Cap
$195.3M
Sector
Healthcare
Industry
Biotechnology
Beta
1.69
52-Wk Range
0.7697-1.99
CEO
Brian Culley
Country
US
Currency
USD

Lineage Cell Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Carlsbad, CA, US. The stock last traded at $0.77, down 5.87% on the session, giving a market capitalisation of $195.3M. On trailing twelve-month figures it carries a trailing P/E of -25.56, a net margin of 16.2%. Its beta of 1.69 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-25.56
Price / Sales
18.02
Price / Book
2.91
EV / EBITDA
-79.21
Gross margin
95.9%
Operating margin
-280.3%
Net margin
16.2%
Return on equity
—
Debt / equity
0.03
Current ratio
5.96
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange Arca
Employees
75
IPO date
1992-03-05
Headquarters
Carlsbad, CA, US
About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Comparable companies

Lineage Cell Therapeutics, Inc. is most often compared with the following Healthcare names:

CELUIPSCMESO
More research on LCTX
LCTX technical analysis LCTX TheEdge Score Compare against peers
Open full interactive analysis & DCF →